Janwillem Naesens - Jun 22, 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc. (CYT)

Role: Director
Signature: /s/ Andrew Gengos, Attorney-in-Fact
Stock symbol: CYT
Transactions as of: Jun 22, 2021
Transactions value $: $4,999,986
Form type: 4
Date filed: 6/24/2021, 08:50 PM
Previous filing: Jun 17, 2021
Next filing: Feb 24, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CYT	Common Stock	Conversion of derivative security		+3.26M			3.26M	Jun 22, 2021	See Footnote	F1, F2
transaction	CYT	Common Stock	Purchase	$5M	+278K	+8.52%	$18.00^*	3.54M	Jun 22, 2021	See Footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CYT	Series B Convertible Preferred Stock	Conversion of derivative security		-10M	-100%		0	Jun 22, 2021	Common Stock	2.93M		See Footnote	F1, F2
transaction	CYT	Series C Convertible Preferred Stock	Conversion of derivative security		-1.11M	-100%		0	Jun 22, 2021	Common Stock	325K		See Footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2	Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by the Reporting Person) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. The Reporting Person, along with Mr. Verelst, disclaim beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein.

Content

Each share of Series B Convertible Preferred Stock and Series C Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.

Shares held by Droia Invest II SCSp. DF II GP Sarl is the general partner of Droia Invest II SCSp. Wepaven BV (represented by the Reporting Person) and IHL SA (represented by Luc Verelst), the managers of DF II GP Sarl, share voting and investment power with respect to the shares held of record by Droia Invest II SCSp. The Reporting Person, along with Mr. Verelst, disclaim beneficial ownership of the securities reported herein, except to the extent of their pecuniary interest therein.